BioVie Inc. (BIVI) — Stock Valuation & Research

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of…

BIVI key statistics

Explore BIVI's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.